This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kaltsas, G. A. Articles by Grossman, A. B. Search for Related Content PubMed PubMed Citation Articles by Kaltsas, G. A. Articles by Grossman, A. B.

The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors

Department of Endocrinology, St. Bartholomew’s Hospital, London EC1A 7BE, United Kingdom

Correspondence: Address all correspondence and requests for reprints to: Prof. A. B. Grossman, Endocrine Oncology, Department of Endocrinology, St. Bartholomew’s Hospital, London EC1A 7BE, United Kingdom. E-mail: a.b.grossman{at}qmul.ac.uk

Neuroendocrine tumors (NETs) constitute a heterogeneous group of neoplasms that originate from endocrine glands such as the pituitary, the parathyroids, and the (neuroendocrine) adrenal, as well as endocrine islets within glandular tissue (thyroid or pancreatic) and cells dispersed between exocrine cells, such as endocrine cells of the digestive (gastroenteropancreatic) and respiratory tracts. Conventionally, NETs may present with a wide variety of functional or nonfunctional endocrine syndromes and may be familial and have other associated tumors. Assessment of specific or general tumor markers offers high sensitivity in establishing the diagnosis and can also have prognostic significance. Imaging modalities include endoscopic ultrasonography, computed tomography and magnetic resonance imaging, and particularly, scintigraphy with somatostatin analogs and metaiodobenzylguanidine. Successful treatment of disseminated NETs requires a multimodal approach; radical tumor surgery may be curative but is rarely possible. Well-differentiated and slow-growing gastroenteropancreatic tumors should be treated with somatostatin analogs or -interferon, with chemotherapy being reserved for poorly differentiated and progressive tumors. Therapy with radionuclides may be used for tumors exhibiting uptake to a diagnostic scan, either after surgery to eradicate microscopic residual disease or later if conventional treatment or biotherapy fails. Maintenance of the quality of life should be a priority, particularly because patients with disseminated disease may experience prolonged survival.

This article has been cited by other articles:

				M. Debono, L.-Q. Hon, N. Bax, A. Blakeborough, and J. Newell-Price Gluteal Nodules in Patients with Metastatic Midgut Carcinoid Disease Treated with Depot Somatostatin Analogs J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1860 - 1864. [Abstract] [Full Text] [PDF]

				A. Chrisoulidou, G. Kaltsas, I. Ilias, and A. B Grossman The diagnosis and management of malignant phaeochromocytoma and paraganglioma Endocr. Relat. Cancer, September 1, 2007; 14(3): 569 - 585. [Abstract] [Full Text] [PDF]

				A Raitila, M Georgitsi, A Karhu, K Tuppurainen, M J Makinen, K Birkenkamp-Demtroder, K Salmenkivi, T F Orntoft, J Arola, V Launonen, et al. No evidence of somatic aryl hydrocarbon receptor interacting protein mutations in sporadic endocrine neoplasia Endocr. Relat. Cancer, September 1, 2007; 14(3): 901 - 906. [Abstract] [Full Text] [PDF]

				E. Vilar, R. Salazar, J. Perez-Garcia, J. Cortes, K. Oberg, and J. Tabernero Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors Endocr. Relat. Cancer, June 1, 2007; 14(2): 221 - 232. [Abstract] [Full Text] [PDF]

				K. Zitzmann, S. Brand, E. N. De Toni, S. Baehs, B. Goke, J. Meinecke, G. Spottl, H. H.H.D. Meyer, and C. J. Auernhammer SOCS1 Silencing Enhances Antitumor Activity of Type I IFNs by Regulating Apoptosis in Neuroendocrine Tumor Cells Cancer Res., May 15, 2007; 67(10): 5025 - 5032. [Abstract] [Full Text] [PDF]

				A. F. Scarsbrook, A. Ganeshan, J. Statham, R. V. Thakker, A. Weaver, D. Talbot, P. Boardman, K. M. Bradley, F. V. Gleeson, and R. R. Phillips Anatomic and Functional Imaging of Metastatic Carcinoid Tumors RadioGraphics, March 1, 2007; 27(2): 455 - 477. [Abstract] [Full Text] [PDF]

				N Fazio, F de Braud, G Delle Fave, and K Oberg Interferon-{alpha} and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination? Ann. Onc., January 1, 2007; 18(1): 13 - 19. [Abstract] [Full Text] [PDF]

				C. Nasr, A. Mason, M. Mayberg, S. M. Staugaitis, and S. L. Asa Acromegaly and Somatotroph Hyperplasia with Adenomatous Transformation Due to Pituitary Metastasis of a Growth Hormone-Releasing Hormone-Secreting Pulmonary Endocrine Carcinoma J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4776 - 4780. [Abstract] [Full Text] [PDF]

				G Capurso, S Lattimore, T Crnogorac-Jurcevic, F Panzuto, M Milione, V Bhakta, N Campanini, S M Swift, C Bordi, G D. Fave, et al. Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. Endocr. Relat. Cancer, June 1, 2006; 13(2): 541 - 558. [Abstract] [Full Text] [PDF]

				F. Panzuto, M. Di Fonzo, E. Iannicelli, R. Sciuto, C. L. Maini, G. Capurso, M. Milione, M. S. Cattaruzza, M. Falconi, V. David, et al. Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma Ann. Onc., March 1, 2006; 17(3): 461 - 466. [Abstract] [Full Text] [PDF]

				S. Ezziddin, T. Logvinski, C. Yong-Hing, H. Ahmadzadehfar, H.-P. Fischer, H. Palmedo, J. Bucerius, M. J. Reinhardt, and H.-J. Biersack Factors Predicting Tracer Uptake in Somatostatin Receptor and MIBG Scintigraphy of Metastatic Gastroenteropancreatic Neuroendocrine Tumors J. Nucl. Med., February 1, 2006; 47(2): 223 - 233. [Abstract] [Full Text] [PDF]

				A. M. Isidori, G. A. Kaltsas, C. Pozza, V. Frajese, J. Newell-Price, R. H. Reznek, P. J. Jenkins, J. P. Monson, A. B. Grossman, and G. M. Besser The Ectopic Adrenocorticotropin Syndrome: Clinical Features, Diagnosis, Management, and Long-Term Follow-Up J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 371 - 377. [Abstract] [Full Text] [PDF]

				G A Kaltsas, D Papadogias, P Makras, and A B Grossman Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues Endocr. Relat. Cancer, December 1, 2005; 12(4): 683 - 699. [Abstract] [Full Text] [PDF]

				G. A. Kaltsas, P. Nomikos, G. Kontogeorgos, M. Buchfelder, and A. B. Grossman Diagnosis and Management of Pituitary Carcinomas J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 3089 - 3099. [Abstract] [Full Text] [PDF]